相关实验视频

Updated: May 20, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

微RNA-146a通过向编程细胞死亡接体1来抑制扩散型大B细胞淋巴瘤的进展和免疫逃避

Yan Li¹, Xiang Wang¹, Kuannv Yang¹

¹Department of Hematology, Hainan Cancer Hospital, Haikou City 570312, Hainan Province, China.

Iranian journal of immunology : IJI

|March 25, 2025

概括

微RNA 146a (miRNA146a) 通过向PD-L1来抑制扩散性大B细胞淋巴瘤 (DLBCL) 的进展,增强抗瘤免疫力. 这一发现突出了miRNA146a作为淋巴瘤的潜在治疗剂.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

微RNA 146a (miRNA146a) 参与瘤抑制,并可能抑制扩散性大B细胞淋巴瘤 (DLBCL) 的进展.
编程死亡配体1 (PD-L1) 对于癌症的免疫检查点调节至关重要,并且与miRNA146a在免疫反应中的作用有关.

研究的目的:

研究miRNA146a在DLBCL中的作用.
确定PD-L1作为DLBCL中miRNA146a的潜在标.
评估miRNA146a在DLBCL治疗中的治疗潜力.

主要方法:

使用定量PCR (qPCR) 来测量DLBCL细胞中的miR-146a和PD-L1表达.
用miR-146a模拟物或空白等离子体对DLBCL细胞进行处理.
与免疫细胞 (PBMCs,CD8+ T细胞,CIK细胞) 的共同培养测试评估了免疫逃避.
生物信息预测和实验验证确定了miR-146a的目标基因.

主要成果:

与正常B细胞相比,DLBCL细胞中的miR-146a水平明显较低.
过度表达miR-146a降低了DLBCL细胞活力,入侵和免疫逃避,同时促进了细胞亡.
证实miR-146a能够准PD-L1,PD-L1的上调可以逆转miR-146a的瘤抑制作用.

结论:

miR-146a通过向PD-L1并增强抗瘤免疫力来抑制DLBCL的进展.
这些发现表明miR-146a在淋巴瘤治疗中具有显著的治疗潜力.

关键词:

抗瘤免疫力抗瘤免疫力细胞因子诱导的杀手细胞因子.这些细胞是DLBCL细胞.扩散大的B细胞淋巴瘤.瘤是一个瘤.

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...